{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:03Z","timestamp":1791327423833,"version":"4.3.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID). Compared with IVIG, SCIG has fewer systemic side effects and, additionally, facilitates home-based treatment. Shared decision-making practice should include discussion of aspects such as patient preference as well as the associated risks and benefits of treatment. We review the available evidence for the use of SCIG treatment in patients with SID, focusing on patient-reported outcomes (PROs). In most studies, there were improvements to health-related quality of life with SCIG treatment, compared with before initiating SCIG without prior IVIG treatment, or after switching to SCIG from IVIG treatment, or a no-SCIG\/IVIG cohort. Treatment satisfaction with SCIG was similar between patients with SID and primary immunodeficiency disease. Patient preference and perception assessments highlighted the benefits of SCIG compared with IVIG, such as ease of use and administration, convenience, and time-effectiveness. In addition, many patients self-administered SCIG at home. Such aspects may be of specific benefit to patients with SID and hematological malignancy by reducing the risk of infection exposure in clinical settings. PRO data may be useful during shared decision-making discussions with patients with SID.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1528414","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:20:10Z","timestamp":1742491210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency"],"prefix":"10.3389","volume":"16","author":[{"given":"Juthaporn","family":"Cowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il-Kang","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gladiator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kamieniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Shahzad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological Malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.04.002","article-title":"Burden of infection in patients with and without secondary immunodeficiency disease following diagnosis of a mature B cell Malignancy","volume":"24","author":"Richter","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel","volume":"58","author":"Jolles","year":"2023","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological Malignancies: focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04297-8","article-title":"Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058121","article-title":"Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological Malignancies, 2004-2010: a surveillance-based study","volume":"8","author":"Huoi","year":"2013","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1538001","article-title":"The use of octagam and gammanorm in immunodeficiency associated with hematological Malignancies: a prospective study from 21 French hematology departments","volume":"24","author":"Benbrahim","year":"2019","journal-title":"Hematology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247717","article-title":"Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies","volume":"16","author":"Cinetto","year":"2021","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","article-title":"Personalized therapy: immunoglobulin replacement for antibody deficiency","volume":"39","author":"Wasserman","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0313","article-title":"Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases","volume":"14","author":"Kobayashi","year":"2022","journal-title":"Immunotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1183482","article-title":"Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies","volume":"12","author":"Blau","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B26","unstructured":"Cutaquig. Product monograph\n          \n          \n          2023"},{"key":"B27","unstructured":"Summary of product characteristics\n          \n          \n          \n          2025"},{"key":"B28","unstructured":"Product information\n          \n          \n          \n          2022"},{"key":"B29","unstructured":"Product monograph\n          \n          \n          \n          2021"},{"key":"B30","unstructured":"Cuvitru 200mg\/ml solution for subcutaneous injection summary of product characteristics\n          \n          \n          2024"},{"key":"B31","unstructured":"Approval of CUVITRU subcutaneous immunoglobulin in Japan for patients with agammaglobulinemia or hypogammaglobulinemia\n          \n          \n          2023"},{"key":"B32","unstructured":"Product summary\n          \n          \n          \n          2024"},{"key":"B33","unstructured":"New Zealand data sheet\n          \n          \n          \n          2021"},{"key":"B34","unstructured":"Patient information leaflet\n          \n          \n          \n          2023"},{"key":"B35","unstructured":"Product summary (Australia)\n          \n          \n          \n          2025"},{"key":"B36","unstructured":"New Zealand datasheet\n          \n          \n          \n          2020"},{"key":"B37","unstructured":"Product monograph\n          \n          \n          \n          2023"},{"key":"B38","unstructured":"Summary of product characteristics\n          \n          \n          \n          2024"},{"key":"B39","unstructured":"Approval to license hizentra\u00ae in Japan for the treatment of primary immunodeficiency and secondary immunodeficiency\n          \n          \n          2013"},{"key":"B40","unstructured":"UK summary of product characteristics\n          \n          \n          \n          2021"},{"key":"B41","unstructured":"Australian product information\n          \n          \n          \n          2022"},{"key":"B42","unstructured":"Xembify. UK summary of product characteristics\n          \n          \n          2025"},{"key":"B43","unstructured":"Takeda announces approval of CUVITRU subcutaneous immunoglobulin in Japan for patients with agammaglobulinemia for hypogammaglobulinemia\n          \n          \n          2023"},{"key":"B44","unstructured":"National Institute for Health and Care Excellence: Shared decision making guideline"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jep.13162","article-title":"Shared decision making: Does a physician\u2019s decision-making style affect patient participation in treatment choices for primary immunodeficiency","volume":"25","author":"Lamb","year":"2019","journal-title":"J Eval Clin Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.06.030","article-title":"A review of shared decision-making: A call to arms for health care professionals","volume":"125","author":"Bukstein","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0193","article-title":"Development of a novel shared decision making aid for primary immunodeficiency diseases","volume":"15","author":"Tzivelekis","year":"2023","journal-title":"Immunotherapy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route","volume":"21","author":"Gardulf","year":"2007","journal-title":"BioDrugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by\u00a0subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2012.03.022","article-title":"Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases","volume":"46","author":"Haddad","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294408","article-title":"Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry","volume":"18","author":"Abadeh","year":"2023","journal-title":"PLoS One"},{"key":"B52","article-title":"Subcutaneous Ig replacement therapy in primary and secondary hypogammaglobulinemia: A retrospective single centre study of 203 patients","volume-title":"Allergy: European Journal of Allergy and Clinical Immunology Conference: 36th Annual Congress of the European Academy of Allergy and Clinical Immunology, EAACI","author":"Cinetto","year":"2017"},{"key":"B53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/eji.201670200","article-title":"Subcutaneous gammaglobulin replacement therapy in chronic lymphocytic leukemia-5 years of experience","volume":"46","author":"Grywalska","year":"2016","journal-title":"Eur J Immunol Conf"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2966","article-title":"Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics","volume":"40","author":"Innocenti","year":"2022","journal-title":"Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00709-8","article-title":"Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study","volume":"18","author":"Keith","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.006","article-title":"The use of 20% subcutaneous immunoglobulin replacement therapy in patients with B cell Non-Hodgkin lymphoma with humoral immune dysfunction after treatment with rituximab","volume":"20","author":"Mustafa","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258529","article-title":"Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic\u00a0lymphocytic leukemia","volume":"16","author":"Mustafa","year":"2021","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"key":"B59","first-page":"218","article-title":"Clinical and quality of life impacts of IVIG and SCIG therapy differ in patients with secondary immunodeficiency compared to those with primary immunodeficiency","volume-title":"Vox Sanguinis Conference: 29th Regional Congress of the ISBT Basel Switzerland","author":"Windegger","year":"2019"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13515","article-title":"Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological Malignancy","volume":"17","author":"Windegger","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"B62","unstructured":"IQVIA\n          Treatment satisfaction questionnaire for medication (TSQM)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-1746-x","article-title":"Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy","volume":"14","author":"Nicolay","year":"2005","journal-title":"Qual Life Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12865-020-00371-y","article-title":"Subcutaneous immunoglobulin in primary immunodeficiency - impact of training and infusion characteristics on patient-reported outcomes","volume":"21","author":"Mallick","year":"2020","journal-title":"BMC Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13223-022-00746-3","article-title":"Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes","volume":"18","author":"Mallick","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0562-3","article-title":"Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six Hizentra(R) studies","volume":"38","author":"Mallick","year":"2018","journal-title":"J Clin Immunol"},{"key":"B67","unstructured":"HyQvia 100 mg\/ml solution for subcutaneous injection summary of product characterisitics"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"Bril","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0371-0","article-title":"Impact of site of care on infection rates among patients with primary immunodeficiency diseases receiving intravenous immunoglobulin therapy","volume":"37","author":"Wasserman","year":"2017","journal-title":"J Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12866","article-title":"Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2\/3 study in Europe in patients with primary immunodeficiencies","volume":"187","author":"Borte","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0327-9","article-title":"Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America","volume":"36","author":"Suez","year":"2016","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1528414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:20:38Z","timestamp":1742491238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1528414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2025.1528414"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1528414","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1528414"}}